Klacid (Clarithromycin)

Clarithromycin inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, blocking the translocation step of peptide chain elongation. This action stops bacterial growth, providing a bacteriostatic effect at standard concentrations and a bactericidal effect at higher levels, especially when supported by the host immune response.

The dosage of Klacid is determined by the prescribing clinician based on the type and severity of infection, patient weight, renal and hepatic function, and other clinical factors. Healthcare professionals tailor the regimen to each individual patient, and no fixed dose is provided here.

Safety data for clarithromycin injection in pregnancy and lactation are limited, and the product is classified as pregnancy category unknown. It should be used only when the potential benefits justify the possible risks to the fetus or infant, and the decision must be made by a qualified healthcare provider.

To order Klacid, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and assistance with import documentation.

Klacid (clarithromycin) offers a broader spectrum against many Gram‑positive and atypical organisms compared with azithromycin, and it has a higher tissue penetration. However, clarithromycin may have more drug‑interaction potential due to CYP3A4 inhibition, while azithromycin generally has fewer interactions but a shorter half‑life.

Klacid injection should be stored at ambient temperature, preferably below 25 °C, in its original packaging. Protect the product from moisture and direct light. Do not freeze. Before administration, inspect the solution for particulate matter and discoloration, and use aseptic technique as per standard intravenous preparation guidelines.

Klacid is given by intravenous infusion. The recommended infusion rate and duration are set by the prescribing clinician, typically over 30 minutes to 1 hour, depending on the dose and patient condition. Administration should be performed by qualified healthcare personnel using sterile equipment and appropriate infusion sets.

Serious adverse events include severe allergic reactions such as anaphylaxis, Clostridioides difficile‑associated colitis, significant liver enzyme elevations indicating hepatic injury, and QT interval prolongation that can lead to life‑threatening cardiac arrhythmias, especially when combined with other QT‑prolonging drugs.

Klacid is contraindicated in patients with a known hypersensitivity to clarithromycin or any macrolide antibiotic. Caution is also advised for individuals with pre‑existing QT prolongation, severe hepatic impairment, or those taking medications that strongly interact with clarithromycin, unless a risk‑benefit assessment justifies use.